Thorne Research Partners on Cognitive Health Supplements and Support

Thorne Research, a developer of nutritional supplements marketed through healthcare practitioners, has partnered with psychiatrist Daniel G. Amen, MD, as well as Integrative Health Resource (IHR), a provider of medical information and consulting services, to co-develop novel nutrition formulations targeting cognitive health. Additionally, the companies aim to create a comprehensive portfolio of cognitive health offerings. In addition to supplements, it will include a wide range of supplemental support exercises.

“Working closely with Dr. Amen and the team at IHR, we plan to develop an unmatched range of outstanding products and support resources designed to improve brain performance,” said Paul Jacobson, CEO, Thorne Research, in a press release.

IHR has developed a variety of innovative health-tracking tools to help individuals suffering from neurological or behavioral disorders, said Thorne. The partnership will give Thorne Research customers access to tools such as online assessments, nutrition tracking tools, and brain enhancement exercise and games.

Dr. Amen is the founder and CEO of Amen Clinics. According to Thorne, Amen pioneered the use of advanced diagnostic tools, such as SPECT imaging, to more accurately characterize neurological disorders and identify new types of mental conditions.

Together, the parties said they will focus on a wide range of mental conditions, including depression, anxiety, attention disorders, chronic stress, and memory challenges.

"Better integrative health tools to monitor and treat mental health and brain performance are a key strategic need for healthcare professionals and their patients," said James B. LaValle, RPh, CEO of IHR. “Brain performance can best be improved by taking daily steps to exercise cognitive function. Our joint venture will offer many new tools to help patients exercise their brain and monitor their cognitive health at home, while also providing healthcare professionals with the resources they need to advise patients on alternative treatments for cognitive impairments.”